Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voest EE, Burris H, J. Oostendorp RL, et al. Among authors: lewis ld. Int J Clin Pharmacol Ther. 2009 Mar;47(3):195-206. doi: 10.5414/cpp47195. Int J Clin Pharmacol Ther. 2009. PMID: 19281729 Clinical Trial.
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD. Goh BC, et al. Among authors: lewis ld. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. Clin Pharmacol Ther. 2010. PMID: 20881954 Clinical Trial.
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Rekić D, Dota C, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: lewis ld. Cancer Chemother Pharmacol. 2023 Aug;92(2):141-150. doi: 10.1007/s00280-023-04555-2. Epub 2023 Jun 27. Cancer Chemother Pharmacol. 2023. PMID: 37368100 Free PMC article.
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: lewis ld. Cancer Chemother Pharmacol. 2023 Sep;92(3):193-203. doi: 10.1007/s00280-023-04554-3. Epub 2023 Jul 2. Cancer Chemother Pharmacol. 2023. PMID: 37394627 Free PMC article. Clinical Trial.
256 results